With this technique there is no surplus embryos.
• It is an alternative for those who claim moral or ethical reasons with in vitro fertilization
20% of the 600,000 couples in our country does not use in vitro fertilization by ethical or moral grounds. Fertilization outside the womb and the fate of surplus embryos to be morally prevent this technique. However, a "version" shorter in vitro fertilization, to allow these couples to have a more natural pregnancy, because the embryo is formed in the uterus of the woman, not in the lab, and no surplus embryos.
The transfer of gametes, is a technique that is about halfway between the artificial insemination and in vitro fertilization. In artificial insemination the sperm are deposited inside the uterus to penetrate the egg and fertile, but it is a technique with limited results, only achieved a 12% success rate per cycle. In the in vitro fertilization (IVF) fertilization is performed in the laboratory, eggs were extracted by puncture of women through the vagina, and fertility of the male sperm in the laboratory. After a few days, the embryos-usually two, are deposited in the womb. Supernumerary embryos is permitted crioconservan in banks for a maximum of 5 years. It is the technique most commonly used by couples (or single women) with the fertility of either male or female or both (obstruction of the fallopian tubes, endometriosis, male infertility, infertility of unknown origin, changes in ovulation, age ...) The average rate of pregnancy with IVF is approximately 45%.
"With the technical transfer of gametes (the female gamete is the ovum and sperm is the male gamete) what we do is extract the eggs and, within hours, transfer them with sperm to the womb, without waiting for have been fertilized. The embryo is formed inside the woman, "says Dr. Dr. Alfonso de la Fuente, with over 15 years of experience in assisted reproductive technologies and director of the Fertility Institute of Madrid, whose team has achieved successfully perform this technique after an upgrade of its methodology.
Dr. Alfonso de la Fuente.
"The steps are the same as an in vitro fertilization, preparing women through stimulation of ovulation. The purpose is to obtain the development of several follicles, inside which are eggs This process is usually monitored by ultrasound vaginal reporting the number and size of developing follicles.
The eggs are extracted through the puncture and aspiration of ovarian follicles, low vision and vaginal ultrasound. This intervention is usually done on an outpatient basis and requires an anesthetic and sedation during a subsequent observation period varies.
Once the eggs are prepared and graded in the laboratory. Select the most suitable sperm. Grown in the laboratory together under favorable conditions, for a few hours and then be able to transfer sperm to the oocyte 3 uterine cavity, is waiting for the fertilization and embryo implantation.
It is a "more natural, with results not so good as in traditional in vitro fertilization, but higher than in artificial insemination, are around 28-29% success. It is also a more economical technique, on 30-35% less than in vitro fertilization, because the laboratory, the most expensive, is much shorter.
"A few years ago we used a similar technique, but instead of transferring gametes to the uterus, were transferred to the fallopian tube, where fertilization normally occurs in the egg and sperm. It was thought that this would encourage pregnancy but was abandoned because it required a more complex surgical procedure for women and the results were not relevant. "
"This says Dr. Alfonso de la Fuente is an alternative for couples unable to have children and do not accept the conditions posed ethical IVF (frozen embryo extracorporeal fertilization) or who have failed in several attempts in vitro fertilization (repeated failure of implantation). "
80% of pregnancies are achieved in the first three cycles
The factors that determine the likelihood of pregnancy are the cause of infertility, age of the patient, the number of ova obtained and the quality of sperm.
"However, we must bear in mind that not all patients who begin treatment achieved follicular development suitable to be subjected to the puncture, and not all who reach this stage can receive transfer of eggs / sperm, since in some cases failed to obtain eggs or sperm do not have the appropriate conditions. "
The European Institute of Fertility is dedicated exclusively to studying and treating disorders related to reproduction. Is headed by Dr. Alfonso de la Fuente, with over 15 years of experience in this field and has been an associate professor at the Autonomous University of Madrid.
C / General Rodrigo, 6 - 28003 Madrid. Tel: 91 543 99 40 - http://www.iefertilidad.com.
Sunday, February 15, 2009
Hospital de Sant Boi implant with the HP Electronic Medical Record.
Hospital de Sant Boi implant with the HP Electronic Medical Record.
The project involves a total investment of more than 800,000 euros
Hospital de Sant Boi, part of the Hospitaller Order of St John of God, he has more than 800,000 euros to the implementation of electronic patient record, with the help of HP. This project, which involves deploying HP-HCIS, the integrated information system for the health sector of Hewlett-Packard, and consolidate hospital andalusia andalusia andalusia owned group as a reference in the field of ICT sector.
According to Dr. Ramón Rosa, Managing Director of the Hospital de Sant Boi, "This project represents a transformation in the current management of the center and meets the need of providing quality care to the population. On the other hand, provides a flexibility in the care process, ensuring maximum security and confidentiality of information. This project, which encompasses the whole organization, is the result of commitment to the demands of today's society. Not only do we want to improve the structure, but we seek professional excellence to provide the reference population. "
A project in two phases
The introduction of HP-HCIS assumed that the health center to become one of the most advanced from a technological point of view, which would have identified two distinct phases. A first "administrative" to be held in nine months, which will carry out the deployment of administrative tools that are responsible for all efforts that affect the patients. Among them, the modules of hospital admissions and emergency summons, filing of medical records or management of waiting lists and surgical block.
Once this process is beginning a second phase "clinic", which will put everything on the history of the patients, the Clinical Work Station, Applications Manager, Protocolos Care Nursing Clinics and different trajectories care management tools. The entire project will be completed before the transfer from hospital to a new and modern facilities being built, and double its current capacity.
"Increasingly, health centers that are bidding for the HP-HCIS time to implement the electronic patient record," says Enrique Solbes, Director of HP Consulting & Integration for Spain and Portugal. "Undoubtedly, this agreement with the Hospital de Sant Boi is going to allow this center to become consolidated as one of the most advanced from a technological point of view, and that HP is still contributing to the continuous improvement of the Spanish health system."
More than 20 years of experience in the health sector
HP Spanish has about 20 years of experience in developing solutions for hospital information systems. During this time, the company has made to all projects in-depth knowledge, experience and functionality of the systems HIS HP-1 and HP-HIS2, in more than one hundred hospitals throughout Spain.
Only in the last year information systems the company has managed to control were 1,200,000 hospitalizations, stays 9,450,000, 5,400,000 emergency interventions and 800,000 citations 25000000.
Moreover, Spain is a place of reference worldwide, with a competence center with over 150 health professionals.
About the Hospital de Sant Boi
Hospital de Sant Boi, opened in 1978, accumulating 30 years within the health sector and several people attending the Baix Llobregat. In January 2006, the Hospitaller Order of St John of God Hospital and acquire new management promotes a strategic plan in promoting organizational values and based on the quality of care. The new hospital will provide more and better health coverage, promoting the welfare of our users.
About HP
HP, the technology company world's largest IT products and services offered by printing and personal computing, software and solutions that provide the best technology experience for consumers and businesses. HP completed its acquisition of EDS on August 26, 2008. More information about HP (NYSE: HPQ) is available at http://www.hp.com.
The project involves a total investment of more than 800,000 euros
Hospital de Sant Boi, part of the Hospitaller Order of St John of God, he has more than 800,000 euros to the implementation of electronic patient record, with the help of HP. This project, which involves deploying HP-HCIS, the integrated information system for the health sector of Hewlett-Packard, and consolidate hospital andalusia andalusia andalusia owned group as a reference in the field of ICT sector.
According to Dr. Ramón Rosa, Managing Director of the Hospital de Sant Boi, "This project represents a transformation in the current management of the center and meets the need of providing quality care to the population. On the other hand, provides a flexibility in the care process, ensuring maximum security and confidentiality of information. This project, which encompasses the whole organization, is the result of commitment to the demands of today's society. Not only do we want to improve the structure, but we seek professional excellence to provide the reference population. "
A project in two phases
The introduction of HP-HCIS assumed that the health center to become one of the most advanced from a technological point of view, which would have identified two distinct phases. A first "administrative" to be held in nine months, which will carry out the deployment of administrative tools that are responsible for all efforts that affect the patients. Among them, the modules of hospital admissions and emergency summons, filing of medical records or management of waiting lists and surgical block.
Once this process is beginning a second phase "clinic", which will put everything on the history of the patients, the Clinical Work Station, Applications Manager, Protocolos Care Nursing Clinics and different trajectories care management tools. The entire project will be completed before the transfer from hospital to a new and modern facilities being built, and double its current capacity.
"Increasingly, health centers that are bidding for the HP-HCIS time to implement the electronic patient record," says Enrique Solbes, Director of HP Consulting & Integration for Spain and Portugal. "Undoubtedly, this agreement with the Hospital de Sant Boi is going to allow this center to become consolidated as one of the most advanced from a technological point of view, and that HP is still contributing to the continuous improvement of the Spanish health system."
More than 20 years of experience in the health sector
HP Spanish has about 20 years of experience in developing solutions for hospital information systems. During this time, the company has made to all projects in-depth knowledge, experience and functionality of the systems HIS HP-1 and HP-HIS2, in more than one hundred hospitals throughout Spain.
Only in the last year information systems the company has managed to control were 1,200,000 hospitalizations, stays 9,450,000, 5,400,000 emergency interventions and 800,000 citations 25000000.
Moreover, Spain is a place of reference worldwide, with a competence center with over 150 health professionals.
About the Hospital de Sant Boi
Hospital de Sant Boi, opened in 1978, accumulating 30 years within the health sector and several people attending the Baix Llobregat. In January 2006, the Hospitaller Order of St John of God Hospital and acquire new management promotes a strategic plan in promoting organizational values and based on the quality of care. The new hospital will provide more and better health coverage, promoting the welfare of our users.
About HP
HP, the technology company world's largest IT products and services offered by printing and personal computing, software and solutions that provide the best technology experience for consumers and businesses. HP completed its acquisition of EDS on August 26, 2008. More information about HP (NYSE: HPQ) is available at http://www.hp.com.
Technology Spanish, at the World Congress of Internal Medicine.
ITHACA-TSB and TSB Solutions presented their main research-oriented monitoring of chronic patients and home hospitalization.
- Issues such as the use of devices to monitor chronically ill patients using mobile devices and wireless technology aroused great interest to the attendees.
Last September, ending in Buenos Aires on 29 th World Congress of Internal Medicine. With more than 10,000 sessions of Congress and 85 clinics, was a resounding success in terms of participation and the quality and quantity of papers and communications.
In this context, Dr. Ignacio Basagoiti presented the paper "Technology and computer in the monitoring of patients and quality of life", which outlined the major developments and research ITACA-TSB Group of the Polytechnic University of Valencia, as well as of products developed by its spin-off TSB solutions.
Thus, issues such as the use of devices to monitor chronically ill patients using wireless technology and mobile devices as "derma rolling" to monitor skin lesions, cardiovascular disease Ritmus for mobile, MSV for monitoring vital signs, for SPHERAmobile the location and identification, aroused great interest to the attendees.
Similarly, TSB Solutions submitted its application in development for Home hospitalization units. The system is optimized in a way that facilitates the daily work and gives the unit more efficient, providing quick access from anywhere on the structured clinical information, thus avoiding problems such as duplication, loss of data or transcription errors and facilitating communication and integration with other information systems. This solution is currently deployed at Hospital La Fe (Valencia), Hospital Virgen de los Lirios (Alcoy) and Hospital Marqués de Valdecilla (Santander). Furthermore, it showed how solutions with TSB-TSB ITACA are participating in the construction of functional modules related to inpatient units to address the corporate agenda of the Generalitat Valenciana, ORION.
Finally, Dr. Basagoiti presented new research group, highlighting the developments in Web 2.0 based on a philosophy of patient-centered medicine. Specifically, the project Salupedia developed with funding from the Ministry of Industry within the forward plan for digital content, aims to provide patients and citizens in general health information quality recommended and selected by a community of health professionals, so that to constitute a complete open and collaborative medical encyclopedia.
About ITACA-TSB
ITHACA-TSB is a group of excellence dedicated to the development and transfer of applications of new technologies for improving quality of life: telemedicine and e-health, e-inclusion and infoaccesibilidad, Ambient Intelligence (AMI), health information, Quality Web.
ITHACA-TSB plans to implement initiatives to promote health, specifically on issues such as physical activity and healthy eating habits, creating scenarios where integration techniques are telemonitorización vital signs, knowledge management, application of motivational strategies, and much more .
TSB ITACA belongs to the Institute of the Polytechnic University of Valencia, and worked in major European projects such as Metabo, Persona, PIPS, My Heart, Oasis, etc.. It also offers solutions for institutions and companies as Educasalud (Fundación Telefónica), Digital Cities (Albany, Santander), WiMax (Ayto Sagunto), home hospitalization (Hospital La Fe), Ambulatory Surgery (Hospital Dr. Peset, etc.).
About TSB Solutions
TSB Solutions Inc. is a company dedicated to introducing and developing new technologies for personalized health care and welfare, improving the quality of life and creating new business opportunities based on their technological capabilities and research.
TSB Solutions Inc. Founded in January 2008 as a spin-off of the Institute ITACA of the Polytechnic University of Valencia. Based on the experience of over ten years of research for health-sector partner, and thanks to its structure and alliances, TSB SOLUTIONS SA has the capacity to effectively assess and exploit the business potential of R & D more relevant to the sector, bringing to the market new products and solutions that meet the demands of our customers.
Furthermore TSB SOLUTIONS S.A. has an extensive network of personal and professional relationships with Spanish, European and multinational, with the government, with NGOs and funding agencies of the R & D, developed in the framework of research projects and contracts made, giving TSB SOLUTIONS SA a broad and deep state of technology, our skills and market to which we are going.
Websites
- ITHACA-http://www.tsb.upv.es TSB.
- TSB Solutions http://www.tsbsoluciones.com.
- Issues such as the use of devices to monitor chronically ill patients using mobile devices and wireless technology aroused great interest to the attendees.
Last September, ending in Buenos Aires on 29 th World Congress of Internal Medicine. With more than 10,000 sessions of Congress and 85 clinics, was a resounding success in terms of participation and the quality and quantity of papers and communications.
In this context, Dr. Ignacio Basagoiti presented the paper "Technology and computer in the monitoring of patients and quality of life", which outlined the major developments and research ITACA-TSB Group of the Polytechnic University of Valencia, as well as of products developed by its spin-off TSB solutions.
Thus, issues such as the use of devices to monitor chronically ill patients using wireless technology and mobile devices as "derma rolling" to monitor skin lesions, cardiovascular disease Ritmus for mobile, MSV for monitoring vital signs, for SPHERAmobile the location and identification, aroused great interest to the attendees.
Similarly, TSB Solutions submitted its application in development for Home hospitalization units. The system is optimized in a way that facilitates the daily work and gives the unit more efficient, providing quick access from anywhere on the structured clinical information, thus avoiding problems such as duplication, loss of data or transcription errors and facilitating communication and integration with other information systems. This solution is currently deployed at Hospital La Fe (Valencia), Hospital Virgen de los Lirios (Alcoy) and Hospital Marqués de Valdecilla (Santander). Furthermore, it showed how solutions with TSB-TSB ITACA are participating in the construction of functional modules related to inpatient units to address the corporate agenda of the Generalitat Valenciana, ORION.
Finally, Dr. Basagoiti presented new research group, highlighting the developments in Web 2.0 based on a philosophy of patient-centered medicine. Specifically, the project Salupedia developed with funding from the Ministry of Industry within the forward plan for digital content, aims to provide patients and citizens in general health information quality recommended and selected by a community of health professionals, so that to constitute a complete open and collaborative medical encyclopedia.
About ITACA-TSB
ITHACA-TSB is a group of excellence dedicated to the development and transfer of applications of new technologies for improving quality of life: telemedicine and e-health, e-inclusion and infoaccesibilidad, Ambient Intelligence (AMI), health information, Quality Web.
ITHACA-TSB plans to implement initiatives to promote health, specifically on issues such as physical activity and healthy eating habits, creating scenarios where integration techniques are telemonitorización vital signs, knowledge management, application of motivational strategies, and much more .
TSB ITACA belongs to the Institute of the Polytechnic University of Valencia, and worked in major European projects such as Metabo, Persona, PIPS, My Heart, Oasis, etc.. It also offers solutions for institutions and companies as Educasalud (Fundación Telefónica), Digital Cities (Albany, Santander), WiMax (Ayto Sagunto), home hospitalization (Hospital La Fe), Ambulatory Surgery (Hospital Dr. Peset, etc.).
About TSB Solutions
TSB Solutions Inc. is a company dedicated to introducing and developing new technologies for personalized health care and welfare, improving the quality of life and creating new business opportunities based on their technological capabilities and research.
TSB Solutions Inc. Founded in January 2008 as a spin-off of the Institute ITACA of the Polytechnic University of Valencia. Based on the experience of over ten years of research for health-sector partner, and thanks to its structure and alliances, TSB SOLUTIONS SA has the capacity to effectively assess and exploit the business potential of R & D more relevant to the sector, bringing to the market new products and solutions that meet the demands of our customers.
Furthermore TSB SOLUTIONS S.A. has an extensive network of personal and professional relationships with Spanish, European and multinational, with the government, with NGOs and funding agencies of the R & D, developed in the framework of research projects and contracts made, giving TSB SOLUTIONS SA a broad and deep state of technology, our skills and market to which we are going.
Websites
- ITHACA-http://www.tsb.upv.es TSB.
- TSB Solutions http://www.tsbsoluciones.com.
Saturday, February 14, 2009
Gilead outlining their research and development program for 2009.
The biopharmaceutical company presents its latest advances in clinical development during the telephone press conference on the financial results of 2008
Gilead Sciences, Inc. (Nasdaq: GILD), stressed during the telephone press conference on the financial performance of last year, the priorities of its clinical development program for 2009. Among the most significant upgrades include the agreement with the Food and Drug Administration (FDA) U.S. in the clinical development of the following products: elvitegravir, GS 9350 and the fixed dose regimen of elvitegravir GS + 9350 + Truvada ® (emtricitabine and tenofovir disoproxil fumarate). Moreover, the discussion has begun on the timing of communications darusentan clinics for 2009 and progress in the development of compounds to treat hepatitis C virus (HCV) and liver diseases.
"Currently the R & D program of Gilead, is wider than at any other time in our 21 years of history," said Dr. Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientist of Gilead Sciences. "As we enter 2009, we have several candidates for our product development portfolio, including several products that are about to enter Phase III studies and Phase II. Our efforts are directed to a certain therapeutic areas where we believe we are strongly positioned to move forward with our drug and the potential to become the best treatments of their kind. "
HIGHLIGHTS OF R & D PROGRAM FOR 2009:
Developing a new regime of one tablet per day for HIV
Gilead is developing elvitegravir, the integrase inhibitor under investigation for use in HIV patients treated with other antiretrovirals, the GS 9350, a new drug enhancer and a "four-in-one fixed dose (CDF, or fixed-dose combination) for people with HIV, which combines elvitegravir, GS 9350, tenofovir disoproxil fumarate and emtricitabine. Currently, the only once-daily drug is Atripla ® (efavirenz 600 mg / emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg), marketed in the U.S., Canada and Europe by Gilead Sciences and Bristol-Myers Squibb Company and distributed by Merck & Co. Inc. in 94 developing countries.
• The next scientific conference on HIV, Gilead will present the first data in humans in the compressed "in a four." Specifically, the results of Phase I on the leverage effect of the drug GS 9350, both as independent drug as part of the tablet "four-in-one with elvitegravir, tenofovir and emtricitabine.
• With the agreement of the FDA to proceed with the development agenda of the CDF, Gilead plans to initiate a Phase II study in naïve patients in the second quarter of 2009.
Advancing the treatment of liver disease
The 9450 GS is the main candidate of Gilead for the treatment of serious diseases of the liver. It is a novel caspase inhibitor in a daily dose to treat the inflammation and fibrosis, and HCV and non-alcoholic steatohepatitis (NASH).
The non-alcoholic steatohepatitis is a disease characterized by inflammation of the liver caused by an accumulation of fat. This condition is associated with obesity, high cholesterol and diabetes. The National Center for Infectious Diseases in U.S. predicts that by 2025 more than 25 million Americans are affected by this disease.
• The Phase IIa study that evaluated the safety, tolerability, efficacy and pharmacokinetics of GS 9450 in patients infected with HCV has been completed. The data from this study will be presented this year at a medical conference, and Gilead plans to begin a Phase IIb study in the second quarter.
• The Phase IIa study of GS 9450 in patients with non-alcoholic steatohepatitis, to evaluate its safety, tolerability, pharmacokinetics and efficacy was initiated in the third quarter of 2008. The results of this study are expected in the fourth quarter of 2009.
• Gilead is also evaluating a new polymerase inhibitor, the GS 9190, as a potential treatment for HCV. Is already underway in a Phase II study of GS 9190 in combination with pegylated interferon alfa 2a and ribavirin in patients infected with HCV (genotype 1).
Expanding the presence in the cardiovascular area
The main drug in cardiovascular research in the area is darusentan. This drug is an oral receptor antagonist of endothelin (ARE) to treat resistant hypertension. This disease affects approximately 2 to 3 million Americans who fail to reach an optimal blood pressure despite taking three treatments of hypertension drugs including a diuretic.
• The Phase III clinical trials, DAR 311 and DAR 312, waiting to be completed this year, Gilead and provides the data 311 of the DAR will be announced in the second quarter.
• In addition, Gilead is developing cicletanina for pulmonary arterial hypertension (PAH), since early 2009 expected to begin a Phase II clinical trial to assess the pattern of one and two daily doses. Cicletanina is an oral agent that is already approved in some European countries for the treatment of hypertension.
• In the second quarter of 2009, Gilead plans to initiate a Phase III study will evaluate ambrisentan, an oral AER for hypertension associated with idiopathic pulmonary fibrosis.
Identifying the priorities in the area of lung diseases
Gilead continues to focus its efforts on the development of aztreonam lysine for inhalation and ambrisentan to treat idiopathic pulmonary fibrosis. In addition, are evaluating the potential of GS 9310/11 for the treatment of cystic fibrosis and GS 9411 for lung disease.
• Gilead has recently initiated a Phase II study of aztreonam lysine for inhalation in patients with bronchiectasis.
• This month has started a Phase III study of ambrisentan for the treatm of idiopathic pulmonary fibrosis. The ARTEMIS study will include approximately 600 patients at 190 research centers in USA, Canada, Europe, Asia, New Zealand and Australia.
• In the fourth quarter of 2008, we initiated a Phase II study to evaluate the safety and efficacy of GS 9310/11, inhaled and co-formulated with fosfomycin and tobramycin for bacterial infections associated with cystic fibrosis.
• Gilead is also evaluating the safety and tolerability of GS 9411, a new blocker of the epithelial sodium channel is designed to increase airway hydration for treatment of lung disease. The Phase I study was initiated in the fourth quarter of 2008.
The drugs discussed in this press release are investigational and not yet proven its safety or efficacy in humans.
Truvada ® is a trademark owned by Gilead Sciences
Atripla ® is a trademark owned by Bristol-Myers Squibb and Gilead Sciences
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that is dedicated to discover, develop and commercialize innovative therapeutics in areas of medical need that have not been met. The company's mission is to advance the care of patients suffering from diseases that pose a threat to life. Headquartered in Foster City (California), Gilead operates in USA, Europe and Australia.
Gilead Sciences, Inc. (Nasdaq: GILD), stressed during the telephone press conference on the financial performance of last year, the priorities of its clinical development program for 2009. Among the most significant upgrades include the agreement with the Food and Drug Administration (FDA) U.S. in the clinical development of the following products: elvitegravir, GS 9350 and the fixed dose regimen of elvitegravir GS + 9350 + Truvada ® (emtricitabine and tenofovir disoproxil fumarate). Moreover, the discussion has begun on the timing of communications darusentan clinics for 2009 and progress in the development of compounds to treat hepatitis C virus (HCV) and liver diseases.
"Currently the R & D program of Gilead, is wider than at any other time in our 21 years of history," said Dr. Norbert Bischofberger, Executive Vice President of Research and Development and Chief Scientist of Gilead Sciences. "As we enter 2009, we have several candidates for our product development portfolio, including several products that are about to enter Phase III studies and Phase II. Our efforts are directed to a certain therapeutic areas where we believe we are strongly positioned to move forward with our drug and the potential to become the best treatments of their kind. "
HIGHLIGHTS OF R & D PROGRAM FOR 2009:
Developing a new regime of one tablet per day for HIV
Gilead is developing elvitegravir, the integrase inhibitor under investigation for use in HIV patients treated with other antiretrovirals, the GS 9350, a new drug enhancer and a "four-in-one fixed dose (CDF, or fixed-dose combination) for people with HIV, which combines elvitegravir, GS 9350, tenofovir disoproxil fumarate and emtricitabine. Currently, the only once-daily drug is Atripla ® (efavirenz 600 mg / emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg), marketed in the U.S., Canada and Europe by Gilead Sciences and Bristol-Myers Squibb Company and distributed by Merck & Co. Inc. in 94 developing countries.
• The next scientific conference on HIV, Gilead will present the first data in humans in the compressed "in a four." Specifically, the results of Phase I on the leverage effect of the drug GS 9350, both as independent drug as part of the tablet "four-in-one with elvitegravir, tenofovir and emtricitabine.
• With the agreement of the FDA to proceed with the development agenda of the CDF, Gilead plans to initiate a Phase II study in naïve patients in the second quarter of 2009.
Advancing the treatment of liver disease
The 9450 GS is the main candidate of Gilead for the treatment of serious diseases of the liver. It is a novel caspase inhibitor in a daily dose to treat the inflammation and fibrosis, and HCV and non-alcoholic steatohepatitis (NASH).
The non-alcoholic steatohepatitis is a disease characterized by inflammation of the liver caused by an accumulation of fat. This condition is associated with obesity, high cholesterol and diabetes. The National Center for Infectious Diseases in U.S. predicts that by 2025 more than 25 million Americans are affected by this disease.
• The Phase IIa study that evaluated the safety, tolerability, efficacy and pharmacokinetics of GS 9450 in patients infected with HCV has been completed. The data from this study will be presented this year at a medical conference, and Gilead plans to begin a Phase IIb study in the second quarter.
• The Phase IIa study of GS 9450 in patients with non-alcoholic steatohepatitis, to evaluate its safety, tolerability, pharmacokinetics and efficacy was initiated in the third quarter of 2008. The results of this study are expected in the fourth quarter of 2009.
• Gilead is also evaluating a new polymerase inhibitor, the GS 9190, as a potential treatment for HCV. Is already underway in a Phase II study of GS 9190 in combination with pegylated interferon alfa 2a and ribavirin in patients infected with HCV (genotype 1).
Expanding the presence in the cardiovascular area
The main drug in cardiovascular research in the area is darusentan. This drug is an oral receptor antagonist of endothelin (ARE) to treat resistant hypertension. This disease affects approximately 2 to 3 million Americans who fail to reach an optimal blood pressure despite taking three treatments of hypertension drugs including a diuretic.
• The Phase III clinical trials, DAR 311 and DAR 312, waiting to be completed this year, Gilead and provides the data 311 of the DAR will be announced in the second quarter.
• In addition, Gilead is developing cicletanina for pulmonary arterial hypertension (PAH), since early 2009 expected to begin a Phase II clinical trial to assess the pattern of one and two daily doses. Cicletanina is an oral agent that is already approved in some European countries for the treatment of hypertension.
• In the second quarter of 2009, Gilead plans to initiate a Phase III study will evaluate ambrisentan, an oral AER for hypertension associated with idiopathic pulmonary fibrosis.
Identifying the priorities in the area of lung diseases
Gilead continues to focus its efforts on the development of aztreonam lysine for inhalation and ambrisentan to treat idiopathic pulmonary fibrosis. In addition, are evaluating the potential of GS 9310/11 for the treatment of cystic fibrosis and GS 9411 for lung disease.
• Gilead has recently initiated a Phase II study of aztreonam lysine for inhalation in patients with bronchiectasis.
• This month has started a Phase III study of ambrisentan for the treatm of idiopathic pulmonary fibrosis. The ARTEMIS study will include approximately 600 patients at 190 research centers in USA, Canada, Europe, Asia, New Zealand and Australia.
• In the fourth quarter of 2008, we initiated a Phase II study to evaluate the safety and efficacy of GS 9310/11, inhaled and co-formulated with fosfomycin and tobramycin for bacterial infections associated with cystic fibrosis.
• Gilead is also evaluating the safety and tolerability of GS 9411, a new blocker of the epithelial sodium channel is designed to increase airway hydration for treatment of lung disease. The Phase I study was initiated in the fourth quarter of 2008.
The drugs discussed in this press release are investigational and not yet proven its safety or efficacy in humans.
Truvada ® is a trademark owned by Gilead Sciences
Atripla ® is a trademark owned by Bristol-Myers Squibb and Gilead Sciences
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that is dedicated to discover, develop and commercialize innovative therapeutics in areas of medical need that have not been met. The company's mission is to advance the care of patients suffering from diseases that pose a threat to life. Headquartered in Foster City (California), Gilead operates in USA, Europe and Australia.
Laser hair removal is becoming the ultimate solution against sacral fistulas and abscesses.
The research results were published in the journal Dermatologic Surgery, the national expression of the American Society of Dermatology Surgery.
• Those affected by fistulas sacrocoxígeas, mostly boys between 15 and 40 years, have a possibility of recurrence nearly 40 percent, resulting in several cases subsequent surgeries in the same area.
• "All patients with this condition to which we have treated with laser hair removal have experienced a gradual and permanent resolution of the folliculitis, thus avoiding surgery.
• This type of procedure often requires a number of meetings varies depending on the patient and the cyst, but usually between three and eleven.
• "The laser hair removal should be considered as a treatment of choice for abscesses and fistulas sacrocoxígeas.
One of the major problems of those affected by abscesses and fistulas sacrocoxígeas, mostly boys between 15 and 40 years, is the high probability of relapse (a percentage close to 40 per cent). In contrast, laser hair removal interglúteo fold is an effective and durable treatment for folliculitis and reduce their risk of recurrence, thus avoiding a possible surgery.
Doctors Nerea Landa, José Luis Azpiazu have conducted an investigation in which the performance of the many treatments they have done to patients with recurrent fistulas Dermitek clinic in Bilbao since 1999. "Many patients have found an alternative to the traditional non-invasive surgery that provides a durable long-term outcome," says the dermatologist Nerea Landa. This study has been published in the journal Dermatologic Surgery, the national expression of the American Society of Dermatology Surgery. Still, "the scientific production in this area remains limited," say the authors.
The most severe cases of fistula sacrocoxígeas often require invasive treatments such as surgical excision or incision and drainage. When the infection is mild, treatment with an antibiotic or depilatory creams can be effective, although it is true, said Landa, who "unfortunately, in many cases the disease becomes a play and leads the patient to one, two or three surgeries. "
Avoid this constant, ie the usual recurrence, was the main objective of Dermitek investigators, who found in laser hair removal fold interglúteo a effective treatment against the sacral fistulas and abscesses in this area, "as the doctor Jose Luis Azpiazu.
Combining an alexandrite laser with intense pulsed light, have achieved "a progressive decline of infectious folliculitis-like hair loss in interglúteo-fold," says the dermatologist Nerea Landa. This type of treatment often requires a number of sessions varies, depending on the cyst and the patient, between three and eleven. In addition there have been no side effects in this study and, as Azpiazu, "has a high degree of satisfaction." Since Dermitek even say that "to date, none of the cases we have tried has been clarified further surgery because of this."
Prevention
One of the things that stand out from the investigation by Landa and Azpiazu is that data can be extrapolated to apply to medical prevention. "People whose parents have suffered sacral fistulas or abscesses have a high probability of ending the suffering that they, too," says the dermatologist.
Therefore, before the onset of symptoms prior to infection, which often manifest as a series of granite into the fold interglúteo, it is advisable to pluck the area because the hair just frozen in that area on many occasions in abscesses and subsequently recurrent sacral fistulas in the worst case, must be operated, with obvious discomfort and risks that this entails for those who suffer. "
A recurrent infection
The infectious folliculitis is characterized by frequent recurrences after treatment, and although it is known that the main determinant in their occurrence is due to the infection of hair frozen (along with other risk factors such as obesity and sweat frequently in interglútea area), is still not easy to prevent it. Despite this, physicians Dermitek out that "all patients with this condition to which we have treated with laser hair removal have experienced a gradual and permanent resolution of the folliculitis.
Among those affected by this pathology is the group of athletes, and ensures that as Azpiazu "is a condition that occurs frequently in certain sports," who adds that "athletes who have tried in the clinic have been a free problem that in most cases, have suffered for several years. "
Under the terms of the physicians, "laser hair removal should be considered as a treatment of choice for abscesses and fistulas sacrocoxígeas.
• Those affected by fistulas sacrocoxígeas, mostly boys between 15 and 40 years, have a possibility of recurrence nearly 40 percent, resulting in several cases subsequent surgeries in the same area.
• "All patients with this condition to which we have treated with laser hair removal have experienced a gradual and permanent resolution of the folliculitis, thus avoiding surgery.
• This type of procedure often requires a number of meetings varies depending on the patient and the cyst, but usually between three and eleven.
• "The laser hair removal should be considered as a treatment of choice for abscesses and fistulas sacrocoxígeas.
One of the major problems of those affected by abscesses and fistulas sacrocoxígeas, mostly boys between 15 and 40 years, is the high probability of relapse (a percentage close to 40 per cent). In contrast, laser hair removal interglúteo fold is an effective and durable treatment for folliculitis and reduce their risk of recurrence, thus avoiding a possible surgery.
Doctors Nerea Landa, José Luis Azpiazu have conducted an investigation in which the performance of the many treatments they have done to patients with recurrent fistulas Dermitek clinic in Bilbao since 1999. "Many patients have found an alternative to the traditional non-invasive surgery that provides a durable long-term outcome," says the dermatologist Nerea Landa. This study has been published in the journal Dermatologic Surgery, the national expression of the American Society of Dermatology Surgery. Still, "the scientific production in this area remains limited," say the authors.
The most severe cases of fistula sacrocoxígeas often require invasive treatments such as surgical excision or incision and drainage. When the infection is mild, treatment with an antibiotic or depilatory creams can be effective, although it is true, said Landa, who "unfortunately, in many cases the disease becomes a play and leads the patient to one, two or three surgeries. "
Avoid this constant, ie the usual recurrence, was the main objective of Dermitek investigators, who found in laser hair removal fold interglúteo a effective treatment against the sacral fistulas and abscesses in this area, "as the doctor Jose Luis Azpiazu.
Combining an alexandrite laser with intense pulsed light, have achieved "a progressive decline of infectious folliculitis-like hair loss in interglúteo-fold," says the dermatologist Nerea Landa. This type of treatment often requires a number of sessions varies, depending on the cyst and the patient, between three and eleven. In addition there have been no side effects in this study and, as Azpiazu, "has a high degree of satisfaction." Since Dermitek even say that "to date, none of the cases we have tried has been clarified further surgery because of this."
Prevention
One of the things that stand out from the investigation by Landa and Azpiazu is that data can be extrapolated to apply to medical prevention. "People whose parents have suffered sacral fistulas or abscesses have a high probability of ending the suffering that they, too," says the dermatologist.
Therefore, before the onset of symptoms prior to infection, which often manifest as a series of granite into the fold interglúteo, it is advisable to pluck the area because the hair just frozen in that area on many occasions in abscesses and subsequently recurrent sacral fistulas in the worst case, must be operated, with obvious discomfort and risks that this entails for those who suffer. "
A recurrent infection
The infectious folliculitis is characterized by frequent recurrences after treatment, and although it is known that the main determinant in their occurrence is due to the infection of hair frozen (along with other risk factors such as obesity and sweat frequently in interglútea area), is still not easy to prevent it. Despite this, physicians Dermitek out that "all patients with this condition to which we have treated with laser hair removal have experienced a gradual and permanent resolution of the folliculitis.
Among those affected by this pathology is the group of athletes, and ensures that as Azpiazu "is a condition that occurs frequently in certain sports," who adds that "athletes who have tried in the clinic have been a free problem that in most cases, have suffered for several years. "
Under the terms of the physicians, "laser hair removal should be considered as a treatment of choice for abscesses and fistulas sacrocoxígeas.
The SEIMC warning about the increase of sexually transmitted infections in Spain.
• Cases of syphilis have doubled in Spain in just a decade, according to the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)
• Infections by the human papilloma virus, in 15 years, have increased in our country nearly 50% among men and among women has tripled
• STIs have risen in our country due to changes in social behavior, migration and travel abroad
The Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC), which comprises the vast majority of clinical microbiologists and infectious disease specialists Spanish, warning about the increasing cases of sexually transmitted infections in our country in the last 10 years.
According to the World Health Organization syphilis, gonorrhea, chlamydia and trichomonas the daily affect more than one million people each year, appearing 340 million new cases. In Spain, syphilis is a disease that has increased because, in just ten years, due to this infection cases have come to achieving the 1734, doubling in just one decade.
A person suffering from an infection when a microorganism (virus, bacterium or parasite) is present in your body. The infected person does not necessarily have to have symptoms, do not feel sick, but transmits the organism causing the infection. Sexually transmitted infections are spread during sexual intercourse with infected and unprotected.
STD in our country
According to the ITS units of Oviedo and Gijón, dependent Monte Naranco Hospital of Oviedo, infection with human papilloma virus affected the late eighties, to 55,000 men and 10,000 women, while 15 years later the number of cases has risen by 50% among men and among women has tripled. According to Dr. Fernando Vazquez, section chief of the Hospital Basic Services Monte Naranco and member of the SEIMC: "Sexually transmitted infections spread, among other things, for lack of being infected because the symptoms are not easily detectable . If you recognize any symptoms or have unprotected sex or non-partners is necessary to apply as soon as possible to the doctor to a specialist in ITS, a microbiologist and infectologists or specialists such as gynecologists, dermatologists or urologists.
Similarly, STI services in this hospital have warned about the increasing cases of people infected with gonorrhea and chlamydia. After ten years getting Decreasing numbers, it appears that since 2000 they have gradually increased in both men and women. Both are infections that affect the urethra, in the case of men, and cervix in women. These two diseases affect more to gay men than heterosexuals and 8% of prostitutes in the case of chlamydia in our country. According to Dr. Vázquez, "The best way to avoid this type of disease in sexually active with multiple partners is the protection of condoms through the barrier more effectively, other methods are not as spermicidal creams and pessaries . Moreover, it is essential to avoid sex with people who have STIs until completely cured. "
A worrying increase
STIs have risen in the last 10 years, both in our country as elsewhere in the world due to various reasons such as changes in social behavior, migration and travel abroad. Such issues have fostered the resurgence of sexually transmitted infections such as lymphogranuloma venereum, more common in countries in tropical and subtropical climates, and that Spain had virtually disappeared.
The SEIMC updated for years and clinical protocols for diagnosis of sexually transmitted infections because of the importance of these diseases today. From the standpoint of diagnosis, he has improved with the application of new technologies such as molecular techniques are more sensitive and allow you to use non-invasive samples such as urine also has improved ability to detect resistant microorganisms antibiotics and rapid diagnostic techniques. The effort of the Company is currently focused on research, information and awareness about the risk of infection by this type of infection because the increased number of cases has increased dramatically in our country.
The SEIMC
The Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) is a scientific society that brings together professionals working in the field of infectious disease, both from a clinical point of view as the diagnosis, treatment and prevention processes infectious.
The main purpose of the SEIMC is to foster, promote and disseminate the study and investigation of the Infectious Diseases and Clinical Microbiology, in terms of epidemiology, pathogenesis, diagnosis, treatment, prevention and control is concerned, as well as their interrelations .
Currently with over 2,400 partners, over 1,400 are for the section of Clinical Microbiology and about 1000 to the Infectious Diseases.
For more information, visit the websites:
http://www.seimc.org/inicio/index.asp
• Infections by the human papilloma virus, in 15 years, have increased in our country nearly 50% among men and among women has tripled
• STIs have risen in our country due to changes in social behavior, migration and travel abroad
The Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC), which comprises the vast majority of clinical microbiologists and infectious disease specialists Spanish, warning about the increasing cases of sexually transmitted infections in our country in the last 10 years.
According to the World Health Organization syphilis, gonorrhea, chlamydia and trichomonas the daily affect more than one million people each year, appearing 340 million new cases. In Spain, syphilis is a disease that has increased because, in just ten years, due to this infection cases have come to achieving the 1734, doubling in just one decade.
A person suffering from an infection when a microorganism (virus, bacterium or parasite) is present in your body. The infected person does not necessarily have to have symptoms, do not feel sick, but transmits the organism causing the infection. Sexually transmitted infections are spread during sexual intercourse with infected and unprotected.
STD in our country
According to the ITS units of Oviedo and Gijón, dependent Monte Naranco Hospital of Oviedo, infection with human papilloma virus affected the late eighties, to 55,000 men and 10,000 women, while 15 years later the number of cases has risen by 50% among men and among women has tripled. According to Dr. Fernando Vazquez, section chief of the Hospital Basic Services Monte Naranco and member of the SEIMC: "Sexually transmitted infections spread, among other things, for lack of being infected because the symptoms are not easily detectable . If you recognize any symptoms or have unprotected sex or non-partners is necessary to apply as soon as possible to the doctor to a specialist in ITS, a microbiologist and infectologists or specialists such as gynecologists, dermatologists or urologists.
Similarly, STI services in this hospital have warned about the increasing cases of people infected with gonorrhea and chlamydia. After ten years getting Decreasing numbers, it appears that since 2000 they have gradually increased in both men and women. Both are infections that affect the urethra, in the case of men, and cervix in women. These two diseases affect more to gay men than heterosexuals and 8% of prostitutes in the case of chlamydia in our country. According to Dr. Vázquez, "The best way to avoid this type of disease in sexually active with multiple partners is the protection of condoms through the barrier more effectively, other methods are not as spermicidal creams and pessaries . Moreover, it is essential to avoid sex with people who have STIs until completely cured. "
A worrying increase
STIs have risen in the last 10 years, both in our country as elsewhere in the world due to various reasons such as changes in social behavior, migration and travel abroad. Such issues have fostered the resurgence of sexually transmitted infections such as lymphogranuloma venereum, more common in countries in tropical and subtropical climates, and that Spain had virtually disappeared.
The SEIMC updated for years and clinical protocols for diagnosis of sexually transmitted infections because of the importance of these diseases today. From the standpoint of diagnosis, he has improved with the application of new technologies such as molecular techniques are more sensitive and allow you to use non-invasive samples such as urine also has improved ability to detect resistant microorganisms antibiotics and rapid diagnostic techniques. The effort of the Company is currently focused on research, information and awareness about the risk of infection by this type of infection because the increased number of cases has increased dramatically in our country.
The SEIMC
The Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) is a scientific society that brings together professionals working in the field of infectious disease, both from a clinical point of view as the diagnosis, treatment and prevention processes infectious.
The main purpose of the SEIMC is to foster, promote and disseminate the study and investigation of the Infectious Diseases and Clinical Microbiology, in terms of epidemiology, pathogenesis, diagnosis, treatment, prevention and control is concerned, as well as their interrelations .
Currently with over 2,400 partners, over 1,400 are for the section of Clinical Microbiology and about 1000 to the Infectious Diseases.
For more information, visit the websites:
http://www.seimc.org/inicio/index.asp
Solilaser Group - Leaders in the medical-aesthetic
Solilaser Group is a group of companies engaged in product distribution of the medical-aesthetic and physical sports. Group is a dynamic, flexible, efficient and energetic, which was established in April 2001 in Girona by professionals with over 15 years of experience and established track record in the medical-aesthetic.
OUR VALUES
- Providing quality products and services, continuous improvement
- Reliability and commitment
- At the forefront of technology
- Provide results
- Customer Support and full commitment
- Personalization
PHILOSOPHY
- Contribute to improve physical and aesthetic for people using non-invasive, painless and non-ablative.
KEY SUCCESS
- Confidence in our products
- Collaboration with major manufacturer
- Latest Technology
- Medical Studies
- Actual Results
- Logistics carefully
- Reliability and quality, continuous improvement
- Marketing support for our customers
- A shared philosophy with the final
Solilaser Group's headquarters is located in Fornells de la Selva, Girona, and more than 1100 m2 where the Technical Service, a fully equipped training rooms, as well as a team to provide a service according to their needs.
OUR VALUES
- Providing quality products and services, continuous improvement
- Reliability and commitment
- At the forefront of technology
- Provide results
- Customer Support and full commitment
- Personalization
PHILOSOPHY
- Contribute to improve physical and aesthetic for people using non-invasive, painless and non-ablative.
KEY SUCCESS
- Confidence in our products
- Collaboration with major manufacturer
- Latest Technology
- Medical Studies
- Actual Results
- Logistics carefully
- Reliability and quality, continuous improvement
- Marketing support for our customers
- A shared philosophy with the final
Solilaser Group's headquarters is located in Fornells de la Selva, Girona, and more than 1100 m2 where the Technical Service, a fully equipped training rooms, as well as a team to provide a service according to their needs.
Subscribe to:
Posts (Atom)
